Sign in
A consolidated, AI-driven view of financial strength across every rated company in this industry — ranked by Economic Capital Ratio, with the causal reasoning behind each score.
Merrimack Pharmaceuticals INC climbed 287 positions from 288 to 1 due to its excellent Comprehensive Net Income. Clearside Biomedical Inc lost 212 positions from 62 to 274 due to its bad Research and Development. Xynomic Pharmaceuticals Holdings INC entered the 2018 ranking at rank 5, making it the best newcomer.
All 332 rated companies in US Pharma, 2018.
| Rank | Company | Seal | Economic Capital Ratio | Trend |
|---|
How the RealRate model weighs this industry — feature impact, importance, and fit.
The Feature Distribution shows the main industry variables and the distribution of their impact on financial strength. The more important a variable, the broader the distribution. As the effects are calculated relative to the industry average, half of the companies have a positive effect (green) and half have a negative effect (red).
The Feature Importance Graph highlights the most important industry features for the industry. These variables have the greatest impact on financial health, shown as the last variable at the bottom of the causal graph.
The Regression Plot compares the forecasted company valuation with the observed stock market values. A positive correlation suggests that the model effectively explains market prices.
